Pfizer(US:PFE) 247Wallst·2025-11-04 13:00Core Insights - Pfizer's stock has experienced a decline of 9.90% over the past month, following a gain of 10.02% the previous month, resulting in a year-to-date loss of 7.33% and an annual decline of 11.17% [3] - The recent drop in stock price is attributed to the FDA's recommendation limiting COVID-19 vaccines to seniors and certain medical conditions, which poses a challenge for Pfizer's COVID-related revenue [4] - Pfizer's total revenues for FY 2025 are forecasted to be between $61 billion and $64 billion, with oncology sales expected to grow significantly [5] Financial Performance - Pfizer's revenue from COVID products, including Paxlovid and Comirnaty, was $11.1 billion in 2024, but the company is now focusing on non-COVID products to stabilize revenue [4][10] - The company reported a significant drop in stock price, down 20.85% over the past five years and more than 54% since its all-time high in December 2021 [6] - Pfizer's revenue and net income figures from 2015 to 2024 show fluctuations, with a peak revenue of $100.33 billion in 2022 and a net income of $31.37 billion [9] Market Outlook - Analysts project a one-year price target for Pfizer at $28.60, indicating a potential upside of 15.97% from the current share price, with a longer-term forecast of $33.60 by the end of 2025 [12] - The oncology drug market is expected to grow at an 8.1% CAGR from 2025 to 2030, which could benefit Pfizer as it reallocates resources towards this segment [10] - The obesity drug market is forecasted to expand at a 22.3% CAGR from 2025 to 2030, with Pfizer developing a new oral formulation to compete in this space [10] Strategic Partnerships - Pfizer's collaboration with Bristol Myers Squibb on the blood thinner Eliquis generated $1.83 billion in Q4 2024, marking a 14% year-over-year increase [11] - The anticoagulant market, valued at $34.8 billion in 2023, is projected to grow at a 10.2% CAGR from 2024 to 2030, presenting further opportunities for Pfizer [11]